Valuation: Immunovia AB

Market Cap 103M 10.83M 9.28M 8.69M 7.94M 14.99M 1.04B 15.15M 39.97M 521M 40.68M 39.8M 1.72B P/E 2026 *
-1.53x
P/E 2027 * -3.82x
Enterprise Value 67.78M 7.14M 6.12M 5.73M 5.24M 9.88M 684M 9.99M 26.36M 344M 26.83M 26.25M 1.14B EV / Sales 2026 *
21.2x
EV / Sales 2027 * 4.21x
Free-Float
90.23%
Yield 2026 *
-
Yield 2027 * -
1 day-1.18%
1 week-1.43%
Current month-15.48%
1 month-14.24%
3 months-27.54%
6 months-17.41%
Current year-33.13%
1 week 0.14
Extreme 0.1438
0.16
1 month 0.14
Extreme 0.1438
0.19
Current year 0.14
Extreme 0.1438
0.25
1 year 0.14
Extreme 0.1438
0.97
3 years 0.14
Extreme 0.1438
4.73
5 years 0.14
Extreme 0.1438
141.5
10 years 0.14
Extreme 0.1438
298.5
Manager TitleAgeSince
Chief Executive Officer 53 29/04/2023
Chief Tech/Sci/R&D Officer 55 29/04/2024
Chief Tech/Sci/R&D Officer 54 31/01/2024
Director TitleAgeSince
Director/Board Member 72 09/12/2016
Chairman 69 26/05/2023
Director/Board Member 51 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
15/11/22 Buy

Chief Executive Officer

150,000 0.6628%
24/05/22 Buy

Chief Executive Officer

100,000 0.4419%
21/05/22 Buy

Chief Executive Officer

100,000 0.4419%
Change 5-day change 1-year change 3-year change Capi.($)
-1.18%-1.43%-81.44%-85.18% 10.83M
+0.66%+6.77%+26.08%-29.49% 17.58B
-8.93%-15.33%-41.00%+74.40% 1.49B
-1.70%-0.62%-48.06%-81.50% 994M
+1.25%+0.08%-23.64%+25.38% 962M
+0.05%+0.33%+59.38%-4.49% 781M
-2.52%-3.44%-38.47%-46.80% 671M
-3.96%-14.81%-45.93%-50.82% 544M
0.00%+2.91%-39.18%-33.51% 461M
+2.25%+7.16%+69.30%+55.11% 451M
Average -1.41%-1.70%-16.30%-17.69% 2.39B
Weighted average by Cap. -0.21%+1.84%+13.98%-21.64%

Financials

2026 *2027 *
Net sales 3.2M 337K 289K 270K 247K 467K 32.3M 472K 1.24M 16.22M 1.27M 1.24M 53.66M 17.3M 1.82M 1.56M 1.46M 1.34M 2.52M 175M 2.55M 6.73M 87.68M 6.85M 6.7M 290M
Net income -87M -9.17M -7.86M -7.35M -6.72M -12.68M -878M -12.82M -33.83M -441M -34.43M -33.69M -1.46B -76M -8.01M -6.87M -6.42M -5.87M -11.08M -767M -11.2M -29.55M -385M -30.08M -29.43M -1.27B
Net Debt -35M -3.69M -3.16M -2.96M -2.7M -5.1M -353M -5.16M -13.61M -177M -13.85M -13.55M -587M -30M -3.16M -2.71M -2.54M -2.32M -4.37M -303M -4.42M -11.67M -152M -11.87M -11.62M -503M
Logo Immunovia AB
Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.
Employees
18
Date Price Change Volume
25/08/26 SEK 0.1518 -0.65% 952,656
24/08/26 SEK 0.1528 +0.39% 4,958,717
21/08/26 SEK 0.1522 -3.67% 2,623,989
20/08/26 SEK 0.1580 +0.38% 1,687,733
19/08/26 SEK 0.1574 +2.21% 1,347,285

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IMMNOV Stock